Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody

T. Numata; T. Nagatani; K. Shirai; T. Maeda; K. Mae; M. Nakasu; M. Saito; T. Usuda; R. Tsuboi; Y. Okubo

doi:10.1111/ced.13357

Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody

Clinical and Experimental Dermatology ◽

10.1111/ced.13357 ◽

2018 ◽

Vol 43 (3) ◽

pp. 281-285 ◽

Cited By ~ 1

Author(s):

T. Numata ◽

T. Nagatani ◽

K. Shirai ◽

T. Maeda ◽

K. Mae ◽

...

Keyword(s):

Monoclonal Antibody ◽

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Sézary Syndrome ◽

Sezary Syndrome ◽

Deacetylase Inhibitor

Download Full-text

The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin

PLoS ONE ◽

10.1371/journal.pone.0146115 ◽

2016 ◽

Vol 11 (1) ◽

pp. e0146115 ◽

Cited By ~ 6

Author(s):

Lilach Moyal ◽

Nataly Feldbaum ◽

Neta Goldfeiz ◽

Ada Rephaeli ◽

Abraham Nudelman ◽

...

Keyword(s):

Histone Deacetylase ◽

Mycosis Fungoides ◽

Histone Deacetylase Inhibitor ◽

Therapeutic Potential ◽

Sézary Syndrome ◽

Sezary Syndrome ◽

Deacetylase Inhibitor

Download Full-text

Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB – IVA mycosis fungoides/Sézary syndrome

British Journal of Dermatology ◽

10.1111/bjd.14427 ◽

2016 ◽

Vol 175 (1) ◽

pp. 80-88 ◽

Cited By ~ 33

Author(s):

F. Child ◽

P.L. Ortiz‐Romero ◽

R. Alvarez ◽

M. Bagot ◽

R. Stadler ◽

...

Keyword(s):

Histone Deacetylase ◽

Mycosis Fungoides ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Multicentre Trial ◽

Sézary Syndrome ◽

Sezary Syndrome ◽

Stage Ib ◽

Deacetylase Inhibitor ◽

Previously Treated

Download Full-text

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2384-1 ◽

2014 ◽

Vol 73 (3) ◽

pp. 495-501 ◽

Cited By ~ 30

Author(s):

Jennifer J. Wheler ◽

Filip Janku ◽

Gerald S. Falchook ◽

Tiffiny L. Jackson ◽

Siqing Fu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Valproic Acid ◽

Phase I ◽

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Phase I Study ◽

Anti Vegf ◽

Deacetylase Inhibitor

Download Full-text

Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis

Leukemia Research ◽

10.1016/j.leukres.2012.01.027 ◽

2012 ◽

Vol 36 (6) ◽

pp. 749-755 ◽

Cited By ~ 6

Author(s):

Wei Shi ◽

Xiaohong Han ◽

Jiarui Yao ◽

Jianliang Yang ◽

Yuankai Shi

Keyword(s):

Monoclonal Antibody ◽

Mantle Cell Lymphoma ◽

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Hydroxamic Acid ◽

Cell Lymphoma ◽

Suberoylanilide Hydroxamic Acid ◽

Deacetylase Inhibitor ◽

Mantle Cell ◽

Anti Cd20

Download Full-text

147: Low Concentration of a Histone Deacetylase Inhibitor, Depsipeptide (FK228), Enhances the Effect of Gemcitabine and Docetaxel in Hormone Refractory Prostate Cancer Cells

The Journal of Urology ◽

10.1016/s0022-5347(18)30412-9 ◽

2007 ◽

Vol 177 (4S) ◽

pp. 50-51

Author(s):

Masatoshi Kanzaki ◽

Hideaki Kakinuma ◽

Teruaki Kumazawa ◽

Takamitsu Inoue ◽

Mitsuru Saito ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Cells ◽

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Hormone Refractory Prostate Cancer ◽

Prostate Cancer Cells ◽

Low Concentration ◽

Deacetylase Inhibitor ◽

Hormone Refractory

Download Full-text

Structure-activity investigations of Santacruzamate A, a potent histone deacetylase inhibitor isolated from a Panamanian cyanobacterium

Planta Medica ◽

10.1055/s-0032-1320383 ◽

2012 ◽

Vol 78 (11) ◽

Author(s):

CM Pavlik ◽

MJ Balunas

Keyword(s):

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Structure Activity ◽

Deacetylase Inhibitor

Download Full-text

Induction of apoptosis in hepatocellular carcinoma by a novel combination of histone deacetylase inhibitor LBH589

10.1055/s-0039-3402242 ◽

2020 ◽

Author(s):

P Mester ◽

E Aschenbrenner ◽

C Kunst ◽

K Gülow ◽

M Müller-Schilling

Keyword(s):

Hepatocellular Carcinoma ◽

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Deacetylase Inhibitor ◽

Induction Of Apoptosis

Download Full-text

Induction of Apoptosis and Chemosensitization by the Histone Deacetylase Inhibitor Trichostatin in Hepatocellular Carcinoma Cells: Molecular Analysis and RKIP Levels

Forum on Immunopathological Diseases and Therapeutics ◽

10.1615/forumimmundisther.v2.i2.40 ◽

2011 ◽

Vol 2 (2) ◽

pp. 127-135 ◽

Cited By ~ 2

Author(s):

Luigi Inguglia ◽

Monica Notarbartolo ◽

Paola Poma ◽

Manuela Labbozzetta ◽

Natale D'Alessandro

Keyword(s):

Hepatocellular Carcinoma ◽

Histone Deacetylase ◽

Molecular Analysis ◽

Histone Deacetylase Inhibitor ◽

Carcinoma Cells ◽

Hepatocellular Carcinoma Cells ◽

Deacetylase Inhibitor ◽

Histone Deacetylase Inhibitor Trichostatin ◽

Induction Of Apoptosis

Download Full-text

Faculty Opinions recommendation of Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717972967.793469769 ◽

2013 ◽

Author(s):

Wendy Boss

Keyword(s):

Oxidative Stress ◽

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Deacetylase Inhibitor

Download Full-text

Faculty of 1000 evaluation for A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718050520.793482822 ◽

2013 ◽

Author(s):

Burton Eisenberg

Keyword(s):

Phase I ◽

Solid Tumors ◽

Histone Deacetylase ◽

Histone Deacetylase Inhibitor ◽

Phase I Study ◽

Pediatric Patients ◽

Deacetylase Inhibitor

Download Full-text